Therapy with a severe acute respiratory syndrome- associated coronavirus-neutralizing human monoclonal antibody reduces disease severity and viral burden in golden syrian hamsters
Identifieur interne : 000526 ( PascalFrancis/Corpus ); précédent : 000525; suivant : 000527Therapy with a severe acute respiratory syndrome- associated coronavirus-neutralizing human monoclonal antibody reduces disease severity and viral burden in golden syrian hamsters
Auteurs : Anjeanette Roberts ; William D. Thomas ; Jeannette Guarner ; Elaine W. Lamirande ; Gregory J. Babcock ; Thomas C. Greenough ; Leatrice Vogel ; Norman Hayes ; John L. Sullivan ; Sherif Zaki ; Kanta Subbarao ; Donna M. AmbrosinoSource :
- The Journal of infectious diseases [ 0022-1899 ] ; 2006.
Descripteurs français
- Pascal (Inist)
English descriptors
- KwdEn :
Abstract
Background. Immunotherapy with monoclonal antibodies (MAbs) offers safe interventions for the prevention of infection in patients after organ transplantation and for the treatment of cancers and autoimmune diseases. MAb 201 is a severe acute respiratory syndrome-associated coronavirus (SARS-CoV)-specific MAb that prevents establishment of viral replication in vitro and prevents viral replication in vivo when administered prophylactically. The efficacy of MAb 201 in the treatment of SARS was evaluated in golden Syrian hamsters, an animal model that supports SARS-CoV replication to high levels and displays severe pathological changes associated with infection, including pneumonitis and pulmonary consolidation. Methods. Golden Syrian hamsters that were intranasally inoculated with SARS-CoV were treated with various doses of MAb 201 or an irrelevant MAb 24 h after inoculation. Two to 7 days after infection, the hamsters were killed, and their lungs were collected for evaluation of viral titers and pathological findings. Results. Postexposure treatment with MAb 201 can alleviate the viral burden and associated pathological findings in a golden Syrian hamster model of SARS-CoV infection. After a hamster is treated with MAb 201, its viral burden is reduced by 102.4-103.9 50% tissue-culture infectious doses per gram of tissue, and the severity of associated pathological findings, including interstitial pneumonitis and consolidation, is also remarkably reduced. Conclusions. The demonstration of successful postexposure MAb 201 therapy in an animal model that demonstrates viral replication and associated pulmonary pathological findings suggests that MAb 201 may be useful in the arsenal of tools to combat SARS.
Notice en format standard (ISO 2709)
Pour connaître la documentation sur le format Inist Standard.
| pA |
|
|---|
Format Inist (serveur)
| NO : | PASCAL 06-0186247 INIST |
|---|---|
| ET : | Therapy with a severe acute respiratory syndrome- associated coronavirus-neutralizing human monoclonal antibody reduces disease severity and viral burden in golden syrian hamsters |
| AU : | ROBERTS (Anjeanette); THOMAS (William D.); GUARNER (Jeannette); LAMIRANDE (Elaine W.); BABCOCK (Gregory J.); GREENOUGH (Thomas C.); VOGEL (Leatrice); HAYES (Norman); SULLIVAN (John L.); ZAKI (Sherif); SUBBARAO (Kanta); AMBROSINO (Donna M.) |
| AF : | Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health/Bethesda, Maryland/Etats-Unis (1 aut., 4 aut., 7 aut., 11 aut.); Massachusetts Biologic Laboratories, University of Massachusetts Medical School, Jamaica Plain/Etats-Unis (2 aut., 5 aut., 12 aut.); Infectious Disease Pathology Activity, National Center for Infectious Diseases, Centers for Disease Control and Prevention/Atlanta, Georgia/Etats-Unis (3 aut., 8 aut., 10 aut.); Departments of Pediatrics and Molecular Medicine, University of Massachusetts Medical School/Worcester/Etats-Unis (6 aut., 9 aut.) |
| DT : | Publication en série; Niveau analytique |
| SO : | The Journal of infectious diseases; ISSN 0022-1899; Coden JIDIAQ; Etats-Unis; Da. 2006; Vol. 193; No. 5; Pp. 685-692; Bibl. 30 ref. |
| LA : | Anglais |
| EA : | Background. Immunotherapy with monoclonal antibodies (MAbs) offers safe interventions for the prevention of infection in patients after organ transplantation and for the treatment of cancers and autoimmune diseases. MAb 201 is a severe acute respiratory syndrome-associated coronavirus (SARS-CoV)-specific MAb that prevents establishment of viral replication in vitro and prevents viral replication in vivo when administered prophylactically. The efficacy of MAb 201 in the treatment of SARS was evaluated in golden Syrian hamsters, an animal model that supports SARS-CoV replication to high levels and displays severe pathological changes associated with infection, including pneumonitis and pulmonary consolidation. Methods. Golden Syrian hamsters that were intranasally inoculated with SARS-CoV were treated with various doses of MAb 201 or an irrelevant MAb 24 h after inoculation. Two to 7 days after infection, the hamsters were killed, and their lungs were collected for evaluation of viral titers and pathological findings. Results. Postexposure treatment with MAb 201 can alleviate the viral burden and associated pathological findings in a golden Syrian hamster model of SARS-CoV infection. After a hamster is treated with MAb 201, its viral burden is reduced by 102.4-103.9 50% tissue-culture infectious doses per gram of tissue, and the severity of associated pathological findings, including interstitial pneumonitis and consolidation, is also remarkably reduced. Conclusions. The demonstration of successful postexposure MAb 201 therapy in an animal model that demonstrates viral replication and associated pulmonary pathological findings suggests that MAb 201 may be useful in the arsenal of tools to combat SARS. |
| CC : | 002A05C10; 002B05; 002A05F04 |
| FD : | Coronavirus; Homme; Hamster; Traitement; Anticorps neutralisant; Anticorps monoclonal; Microbiologie; Infection; Syndrome respiratoire aigu sévère |
| FG : | Coronaviridae; Nidovirales; Virus; Rodentia; Mammalia; Vertebrata; Appareil respiratoire pathologie; Virose; Poumon pathologie |
| ED : | Coronavirus; Human; Hamster; Treatment; Neutralizing antibody; Monoclonal antibody; Microbiology; Infection; Severe acute respiratory syndrome |
| EG : | Coronaviridae; Nidovirales; Virus; Rodentia; Mammalia; Vertebrata; Respiratory disease; Viral disease; Lung disease |
| SD : | Coronavirus; Hombre; Hamster; Tratamiento; anticuerpo neutralizante; Anticuerpo monoclonal; Microbiología; Infección; Síndrome respiratorio agudo severo |
| LO : | INIST-2052.354000153365310100 |
| ID : | 06-0186247 |
Links to Exploration step
Pascal:06-0186247Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Therapy with a severe acute respiratory syndrome- associated coronavirus-neutralizing human monoclonal antibody reduces disease severity and viral burden in golden syrian hamsters</title><author><name sortKey="Roberts, Anjeanette" sort="Roberts, Anjeanette" uniqKey="Roberts A" first="Anjeanette" last="Roberts">Anjeanette Roberts</name><affiliation><inist:fA14 i1="01"><s1>Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health</s1><s2>Bethesda, Maryland</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>4 aut.</sZ><sZ>7 aut.</sZ><sZ>11 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Thomas, William D" sort="Thomas, William D" uniqKey="Thomas W" first="William D." last="Thomas">William D. Thomas</name><affiliation><inist:fA14 i1="02"><s1>Massachusetts Biologic Laboratories, University of Massachusetts Medical School, Jamaica Plain</s1><s3>USA</s3><sZ>2 aut.</sZ><sZ>5 aut.</sZ><sZ>12 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Guarner, Jeannette" sort="Guarner, Jeannette" uniqKey="Guarner J" first="Jeannette" last="Guarner">Jeannette Guarner</name><affiliation><inist:fA14 i1="03"><s1>Infectious Disease Pathology Activity, National Center for Infectious Diseases, Centers for Disease Control and Prevention</s1><s2>Atlanta, Georgia</s2><s3>USA</s3><sZ>3 aut.</sZ><sZ>8 aut.</sZ><sZ>10 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Lamirande, Elaine W" sort="Lamirande, Elaine W" uniqKey="Lamirande E" first="Elaine W." last="Lamirande">Elaine W. Lamirande</name><affiliation><inist:fA14 i1="01"><s1>Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health</s1><s2>Bethesda, Maryland</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>4 aut.</sZ><sZ>7 aut.</sZ><sZ>11 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Babcock, Gregory J" sort="Babcock, Gregory J" uniqKey="Babcock G" first="Gregory J." last="Babcock">Gregory J. Babcock</name><affiliation><inist:fA14 i1="02"><s1>Massachusetts Biologic Laboratories, University of Massachusetts Medical School, Jamaica Plain</s1><s3>USA</s3><sZ>2 aut.</sZ><sZ>5 aut.</sZ><sZ>12 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Greenough, Thomas C" sort="Greenough, Thomas C" uniqKey="Greenough T" first="Thomas C." last="Greenough">Thomas C. Greenough</name><affiliation><inist:fA14 i1="04"><s1>Departments of Pediatrics and Molecular Medicine, University of Massachusetts Medical School</s1><s2>Worcester</s2><s3>USA</s3><sZ>6 aut.</sZ><sZ>9 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Vogel, Leatrice" sort="Vogel, Leatrice" uniqKey="Vogel L" first="Leatrice" last="Vogel">Leatrice Vogel</name><affiliation><inist:fA14 i1="01"><s1>Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health</s1><s2>Bethesda, Maryland</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>4 aut.</sZ><sZ>7 aut.</sZ><sZ>11 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Hayes, Norman" sort="Hayes, Norman" uniqKey="Hayes N" first="Norman" last="Hayes">Norman Hayes</name><affiliation><inist:fA14 i1="03"><s1>Infectious Disease Pathology Activity, National Center for Infectious Diseases, Centers for Disease Control and Prevention</s1><s2>Atlanta, Georgia</s2><s3>USA</s3><sZ>3 aut.</sZ><sZ>8 aut.</sZ><sZ>10 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Sullivan, John L" sort="Sullivan, John L" uniqKey="Sullivan J" first="John L." last="Sullivan">John L. Sullivan</name><affiliation><inist:fA14 i1="04"><s1>Departments of Pediatrics and Molecular Medicine, University of Massachusetts Medical School</s1><s2>Worcester</s2><s3>USA</s3><sZ>6 aut.</sZ><sZ>9 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Zaki, Sherif" sort="Zaki, Sherif" uniqKey="Zaki S" first="Sherif" last="Zaki">Sherif Zaki</name><affiliation><inist:fA14 i1="03"><s1>Infectious Disease Pathology Activity, National Center for Infectious Diseases, Centers for Disease Control and Prevention</s1><s2>Atlanta, Georgia</s2><s3>USA</s3><sZ>3 aut.</sZ><sZ>8 aut.</sZ><sZ>10 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Subbarao, Kanta" sort="Subbarao, Kanta" uniqKey="Subbarao K" first="Kanta" last="Subbarao">Kanta Subbarao</name><affiliation><inist:fA14 i1="01"><s1>Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health</s1><s2>Bethesda, Maryland</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>4 aut.</sZ><sZ>7 aut.</sZ><sZ>11 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Ambrosino, Donna M" sort="Ambrosino, Donna M" uniqKey="Ambrosino D" first="Donna M." last="Ambrosino">Donna M. Ambrosino</name><affiliation><inist:fA14 i1="02"><s1>Massachusetts Biologic Laboratories, University of Massachusetts Medical School, Jamaica Plain</s1><s3>USA</s3><sZ>2 aut.</sZ><sZ>5 aut.</sZ><sZ>12 aut.</sZ></inist:fA14></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">INIST</idno><idno type="inist">06-0186247</idno><date when="2006">2006</date><idno type="stanalyst">PASCAL 06-0186247 INIST</idno><idno type="RBID">Pascal:06-0186247</idno><idno type="wicri:Area/PascalFrancis/Corpus">000526</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Therapy with a severe acute respiratory syndrome- associated coronavirus-neutralizing human monoclonal antibody reduces disease severity and viral burden in golden syrian hamsters</title><author><name sortKey="Roberts, Anjeanette" sort="Roberts, Anjeanette" uniqKey="Roberts A" first="Anjeanette" last="Roberts">Anjeanette Roberts</name><affiliation><inist:fA14 i1="01"><s1>Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health</s1><s2>Bethesda, Maryland</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>4 aut.</sZ><sZ>7 aut.</sZ><sZ>11 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Thomas, William D" sort="Thomas, William D" uniqKey="Thomas W" first="William D." last="Thomas">William D. Thomas</name><affiliation><inist:fA14 i1="02"><s1>Massachusetts Biologic Laboratories, University of Massachusetts Medical School, Jamaica Plain</s1><s3>USA</s3><sZ>2 aut.</sZ><sZ>5 aut.</sZ><sZ>12 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Guarner, Jeannette" sort="Guarner, Jeannette" uniqKey="Guarner J" first="Jeannette" last="Guarner">Jeannette Guarner</name><affiliation><inist:fA14 i1="03"><s1>Infectious Disease Pathology Activity, National Center for Infectious Diseases, Centers for Disease Control and Prevention</s1><s2>Atlanta, Georgia</s2><s3>USA</s3><sZ>3 aut.</sZ><sZ>8 aut.</sZ><sZ>10 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Lamirande, Elaine W" sort="Lamirande, Elaine W" uniqKey="Lamirande E" first="Elaine W." last="Lamirande">Elaine W. Lamirande</name><affiliation><inist:fA14 i1="01"><s1>Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health</s1><s2>Bethesda, Maryland</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>4 aut.</sZ><sZ>7 aut.</sZ><sZ>11 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Babcock, Gregory J" sort="Babcock, Gregory J" uniqKey="Babcock G" first="Gregory J." last="Babcock">Gregory J. Babcock</name><affiliation><inist:fA14 i1="02"><s1>Massachusetts Biologic Laboratories, University of Massachusetts Medical School, Jamaica Plain</s1><s3>USA</s3><sZ>2 aut.</sZ><sZ>5 aut.</sZ><sZ>12 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Greenough, Thomas C" sort="Greenough, Thomas C" uniqKey="Greenough T" first="Thomas C." last="Greenough">Thomas C. Greenough</name><affiliation><inist:fA14 i1="04"><s1>Departments of Pediatrics and Molecular Medicine, University of Massachusetts Medical School</s1><s2>Worcester</s2><s3>USA</s3><sZ>6 aut.</sZ><sZ>9 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Vogel, Leatrice" sort="Vogel, Leatrice" uniqKey="Vogel L" first="Leatrice" last="Vogel">Leatrice Vogel</name><affiliation><inist:fA14 i1="01"><s1>Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health</s1><s2>Bethesda, Maryland</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>4 aut.</sZ><sZ>7 aut.</sZ><sZ>11 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Hayes, Norman" sort="Hayes, Norman" uniqKey="Hayes N" first="Norman" last="Hayes">Norman Hayes</name><affiliation><inist:fA14 i1="03"><s1>Infectious Disease Pathology Activity, National Center for Infectious Diseases, Centers for Disease Control and Prevention</s1><s2>Atlanta, Georgia</s2><s3>USA</s3><sZ>3 aut.</sZ><sZ>8 aut.</sZ><sZ>10 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Sullivan, John L" sort="Sullivan, John L" uniqKey="Sullivan J" first="John L." last="Sullivan">John L. Sullivan</name><affiliation><inist:fA14 i1="04"><s1>Departments of Pediatrics and Molecular Medicine, University of Massachusetts Medical School</s1><s2>Worcester</s2><s3>USA</s3><sZ>6 aut.</sZ><sZ>9 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Zaki, Sherif" sort="Zaki, Sherif" uniqKey="Zaki S" first="Sherif" last="Zaki">Sherif Zaki</name><affiliation><inist:fA14 i1="03"><s1>Infectious Disease Pathology Activity, National Center for Infectious Diseases, Centers for Disease Control and Prevention</s1><s2>Atlanta, Georgia</s2><s3>USA</s3><sZ>3 aut.</sZ><sZ>8 aut.</sZ><sZ>10 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Subbarao, Kanta" sort="Subbarao, Kanta" uniqKey="Subbarao K" first="Kanta" last="Subbarao">Kanta Subbarao</name><affiliation><inist:fA14 i1="01"><s1>Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health</s1><s2>Bethesda, Maryland</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>4 aut.</sZ><sZ>7 aut.</sZ><sZ>11 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Ambrosino, Donna M" sort="Ambrosino, Donna M" uniqKey="Ambrosino D" first="Donna M." last="Ambrosino">Donna M. Ambrosino</name><affiliation><inist:fA14 i1="02"><s1>Massachusetts Biologic Laboratories, University of Massachusetts Medical School, Jamaica Plain</s1><s3>USA</s3><sZ>2 aut.</sZ><sZ>5 aut.</sZ><sZ>12 aut.</sZ></inist:fA14></affiliation></author></analytic><series><title level="j" type="main">The Journal of infectious diseases</title><title level="j" type="abbreviated">J. infect. dis.</title><idno type="ISSN">0022-1899</idno><imprint><date when="2006">2006</date></imprint></series></biblStruct></sourceDesc><seriesStmt><title level="j" type="main">The Journal of infectious diseases</title><title level="j" type="abbreviated">J. infect. dis.</title><idno type="ISSN">0022-1899</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Coronavirus</term><term>Hamster</term><term>Human</term><term>Infection</term><term>Microbiology</term><term>Monoclonal antibody</term><term>Neutralizing antibody</term><term>Severe acute respiratory syndrome</term><term>Treatment</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Coronavirus</term><term>Homme</term><term>Hamster</term><term>Traitement</term><term>Anticorps neutralisant</term><term>Anticorps monoclonal</term><term>Microbiologie</term><term>Infection</term><term>Syndrome respiratoire aigu sévère</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Background. Immunotherapy with monoclonal antibodies (MAbs) offers safe interventions for the prevention of infection in patients after organ transplantation and for the treatment of cancers and autoimmune diseases. MAb 201 is a severe acute respiratory syndrome-associated coronavirus (SARS-CoV)-specific MAb that prevents establishment of viral replication in vitro and prevents viral replication in vivo when administered prophylactically. The efficacy of MAb 201 in the treatment of SARS was evaluated in golden Syrian hamsters, an animal model that supports SARS-CoV replication to high levels and displays severe pathological changes associated with infection, including pneumonitis and pulmonary consolidation. Methods. Golden Syrian hamsters that were intranasally inoculated with SARS-CoV were treated with various doses of MAb 201 or an irrelevant MAb 24 h after inoculation. Two to 7 days after infection, the hamsters were killed, and their lungs were collected for evaluation of viral titers and pathological findings. Results. Postexposure treatment with MAb 201 can alleviate the viral burden and associated pathological findings in a golden Syrian hamster model of SARS-CoV infection. After a hamster is treated with MAb 201, its viral burden is reduced by 10<sup>2.4</sup>-10<sup>3.9</sup> 50% tissue-culture infectious doses per gram of tissue, and the severity of associated pathological findings, including interstitial pneumonitis and consolidation, is also remarkably reduced. Conclusions. The demonstration of successful postexposure MAb 201 therapy in an animal model that demonstrates viral replication and associated pulmonary pathological findings suggests that MAb 201 may be useful in the arsenal of tools to combat SARS.</div></front></TEI><inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0022-1899</s0></fA01><fA02 i1="01"><s0>JIDIAQ</s0></fA02><fA03 i2="1"><s0>J. infect. dis.</s0></fA03><fA05><s2>193</s2></fA05><fA06><s2>5</s2></fA06><fA08 i1="01" i2="1" l="ENG"><s1>Therapy with a severe acute respiratory syndrome- associated coronavirus-neutralizing human monoclonal antibody reduces disease severity and viral burden in golden syrian hamsters</s1></fA08><fA11 i1="01" i2="1"><s1>ROBERTS (Anjeanette)</s1></fA11><fA11 i1="02" i2="1"><s1>THOMAS (William D.)</s1></fA11><fA11 i1="03" i2="1"><s1>GUARNER (Jeannette)</s1></fA11><fA11 i1="04" i2="1"><s1>LAMIRANDE (Elaine W.)</s1></fA11><fA11 i1="05" i2="1"><s1>BABCOCK (Gregory J.)</s1></fA11><fA11 i1="06" i2="1"><s1>GREENOUGH (Thomas C.)</s1></fA11><fA11 i1="07" i2="1"><s1>VOGEL (Leatrice)</s1></fA11><fA11 i1="08" i2="1"><s1>HAYES (Norman)</s1></fA11><fA11 i1="09" i2="1"><s1>SULLIVAN (John L.)</s1></fA11><fA11 i1="10" i2="1"><s1>ZAKI (Sherif)</s1></fA11><fA11 i1="11" i2="1"><s1>SUBBARAO (Kanta)</s1></fA11><fA11 i1="12" i2="1"><s1>AMBROSINO (Donna M.)</s1></fA11><fA14 i1="01"><s1>Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health</s1><s2>Bethesda, Maryland</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>4 aut.</sZ><sZ>7 aut.</sZ><sZ>11 aut.</sZ></fA14><fA14 i1="02"><s1>Massachusetts Biologic Laboratories, University of Massachusetts Medical School, Jamaica Plain</s1><s3>USA</s3><sZ>2 aut.</sZ><sZ>5 aut.</sZ><sZ>12 aut.</sZ></fA14><fA14 i1="03"><s1>Infectious Disease Pathology Activity, National Center for Infectious Diseases, Centers for Disease Control and Prevention</s1><s2>Atlanta, Georgia</s2><s3>USA</s3><sZ>3 aut.</sZ><sZ>8 aut.</sZ><sZ>10 aut.</sZ></fA14><fA14 i1="04"><s1>Departments of Pediatrics and Molecular Medicine, University of Massachusetts Medical School</s1><s2>Worcester</s2><s3>USA</s3><sZ>6 aut.</sZ><sZ>9 aut.</sZ></fA14><fA20><s1>685-692</s1></fA20><fA21><s1>2006</s1></fA21><fA23 i1="01"><s0>ENG</s0></fA23><fA43 i1="01"><s1>INIST</s1><s2>2052</s2><s5>354000153365310100</s5></fA43><fA44><s0>0000</s0><s1>© 2006 INIST-CNRS. All rights reserved.</s1></fA44><fA45><s0>30 ref.</s0></fA45><fA47 i1="01" i2="1"><s0>06-0186247</s0></fA47><fA60><s1>P</s1></fA60><fA61><s0>A</s0></fA61><fA64 i1="01" i2="1"><s0>The Journal of infectious diseases</s0></fA64><fA66 i1="01"><s0>USA</s0></fA66><fC01 i1="01" l="ENG"><s0>Background. Immunotherapy with monoclonal antibodies (MAbs) offers safe interventions for the prevention of infection in patients after organ transplantation and for the treatment of cancers and autoimmune diseases. MAb 201 is a severe acute respiratory syndrome-associated coronavirus (SARS-CoV)-specific MAb that prevents establishment of viral replication in vitro and prevents viral replication in vivo when administered prophylactically. The efficacy of MAb 201 in the treatment of SARS was evaluated in golden Syrian hamsters, an animal model that supports SARS-CoV replication to high levels and displays severe pathological changes associated with infection, including pneumonitis and pulmonary consolidation. Methods. Golden Syrian hamsters that were intranasally inoculated with SARS-CoV were treated with various doses of MAb 201 or an irrelevant MAb 24 h after inoculation. Two to 7 days after infection, the hamsters were killed, and their lungs were collected for evaluation of viral titers and pathological findings. Results. Postexposure treatment with MAb 201 can alleviate the viral burden and associated pathological findings in a golden Syrian hamster model of SARS-CoV infection. After a hamster is treated with MAb 201, its viral burden is reduced by 10<sup>2.4</sup>-10<sup>3.9</sup> 50% tissue-culture infectious doses per gram of tissue, and the severity of associated pathological findings, including interstitial pneumonitis and consolidation, is also remarkably reduced. Conclusions. The demonstration of successful postexposure MAb 201 therapy in an animal model that demonstrates viral replication and associated pulmonary pathological findings suggests that MAb 201 may be useful in the arsenal of tools to combat SARS.</s0></fC01><fC02 i1="01" i2="X"><s0>002A05C10</s0></fC02><fC02 i1="02" i2="X"><s0>002B05</s0></fC02><fC02 i1="03" i2="X"><s0>002A05F04</s0></fC02><fC03 i1="01" i2="X" l="FRE"><s0>Coronavirus</s0><s2>NW</s2><s5>01</s5></fC03><fC03 i1="01" i2="X" l="ENG"><s0>Coronavirus</s0><s2>NW</s2><s5>01</s5></fC03><fC03 i1="01" i2="X" l="SPA"><s0>Coronavirus</s0><s2>NW</s2><s5>01</s5></fC03><fC03 i1="02" i2="X" l="FRE"><s0>Homme</s0><s5>02</s5></fC03><fC03 i1="02" i2="X" l="ENG"><s0>Human</s0><s5>02</s5></fC03><fC03 i1="02" i2="X" l="SPA"><s0>Hombre</s0><s5>02</s5></fC03><fC03 i1="03" i2="X" l="FRE"><s0>Hamster</s0><s5>03</s5></fC03><fC03 i1="03" i2="X" l="ENG"><s0>Hamster</s0><s5>03</s5></fC03><fC03 i1="03" i2="X" l="SPA"><s0>Hamster</s0><s5>03</s5></fC03><fC03 i1="04" i2="X" l="FRE"><s0>Traitement</s0><s5>05</s5></fC03><fC03 i1="04" i2="X" l="ENG"><s0>Treatment</s0><s5>05</s5></fC03><fC03 i1="04" i2="X" l="SPA"><s0>Tratamiento</s0><s5>05</s5></fC03><fC03 i1="05" i2="X" l="FRE"><s0>Anticorps neutralisant</s0><s5>06</s5></fC03><fC03 i1="05" i2="X" l="ENG"><s0>Neutralizing antibody</s0><s5>06</s5></fC03><fC03 i1="05" i2="X" l="SPA"><s0>anticuerpo neutralizante</s0><s5>06</s5></fC03><fC03 i1="06" i2="X" l="FRE"><s0>Anticorps monoclonal</s0><s5>07</s5></fC03><fC03 i1="06" i2="X" l="ENG"><s0>Monoclonal antibody</s0><s5>07</s5></fC03><fC03 i1="06" i2="X" l="SPA"><s0>Anticuerpo monoclonal</s0><s5>07</s5></fC03><fC03 i1="07" i2="X" l="FRE"><s0>Microbiologie</s0><s5>08</s5></fC03><fC03 i1="07" i2="X" l="ENG"><s0>Microbiology</s0><s5>08</s5></fC03><fC03 i1="07" i2="X" l="SPA"><s0>Microbiología</s0><s5>08</s5></fC03><fC03 i1="08" i2="X" l="FRE"><s0>Infection</s0><s5>09</s5></fC03><fC03 i1="08" i2="X" l="ENG"><s0>Infection</s0><s5>09</s5></fC03><fC03 i1="08" i2="X" l="SPA"><s0>Infección</s0><s5>09</s5></fC03><fC03 i1="09" i2="X" l="FRE"><s0>Syndrome respiratoire aigu sévère</s0><s2>NM</s2><s5>14</s5></fC03><fC03 i1="09" i2="X" l="ENG"><s0>Severe acute respiratory syndrome</s0><s2>NM</s2><s5>14</s5></fC03><fC03 i1="09" i2="X" l="SPA"><s0>Síndrome respiratorio agudo severo</s0><s2>NM</s2><s5>14</s5></fC03><fC07 i1="01" i2="X" l="FRE"><s0>Coronaviridae</s0><s2>NW</s2></fC07><fC07 i1="01" i2="X" l="ENG"><s0>Coronaviridae</s0><s2>NW</s2></fC07><fC07 i1="01" i2="X" l="SPA"><s0>Coronaviridae</s0><s2>NW</s2></fC07><fC07 i1="02" i2="X" l="FRE"><s0>Nidovirales</s0><s2>NW</s2></fC07><fC07 i1="02" i2="X" l="ENG"><s0>Nidovirales</s0><s2>NW</s2></fC07><fC07 i1="02" i2="X" l="SPA"><s0>Nidovirales</s0><s2>NW</s2></fC07><fC07 i1="03" i2="X" l="FRE"><s0>Virus</s0><s2>NW</s2></fC07><fC07 i1="03" i2="X" l="ENG"><s0>Virus</s0><s2>NW</s2></fC07><fC07 i1="03" i2="X" l="SPA"><s0>Virus</s0><s2>NW</s2></fC07><fC07 i1="04" i2="X" l="FRE"><s0>Rodentia</s0><s2>NS</s2></fC07><fC07 i1="04" i2="X" l="ENG"><s0>Rodentia</s0><s2>NS</s2></fC07><fC07 i1="04" i2="X" l="SPA"><s0>Rodentia</s0><s2>NS</s2></fC07><fC07 i1="05" i2="X" l="FRE"><s0>Mammalia</s0><s2>NS</s2></fC07><fC07 i1="05" i2="X" l="ENG"><s0>Mammalia</s0><s2>NS</s2></fC07><fC07 i1="05" i2="X" l="SPA"><s0>Mammalia</s0><s2>NS</s2></fC07><fC07 i1="06" i2="X" l="FRE"><s0>Vertebrata</s0><s2>NS</s2></fC07><fC07 i1="06" i2="X" l="ENG"><s0>Vertebrata</s0><s2>NS</s2></fC07><fC07 i1="06" i2="X" l="SPA"><s0>Vertebrata</s0><s2>NS</s2></fC07><fC07 i1="07" i2="X" l="FRE"><s0>Appareil respiratoire pathologie</s0><s5>13</s5></fC07><fC07 i1="07" i2="X" l="ENG"><s0>Respiratory disease</s0><s5>13</s5></fC07><fC07 i1="07" i2="X" l="SPA"><s0>Aparato respiratorio patología</s0><s5>13</s5></fC07><fC07 i1="08" i2="X" l="FRE"><s0>Virose</s0></fC07><fC07 i1="08" i2="X" l="ENG"><s0>Viral disease</s0></fC07><fC07 i1="08" i2="X" l="SPA"><s0>Virosis</s0></fC07><fC07 i1="09" i2="X" l="FRE"><s0>Poumon pathologie</s0><s5>16</s5></fC07><fC07 i1="09" i2="X" l="ENG"><s0>Lung disease</s0><s5>16</s5></fC07><fC07 i1="09" i2="X" l="SPA"><s0>Pulmón patología</s0><s5>16</s5></fC07><fN21><s1>114</s1></fN21><fN44 i1="01"><s1>OTO</s1></fN44><fN82><s1>OTO</s1></fN82></pA></standard><server><NO>PASCAL 06-0186247 INIST</NO><ET>Therapy with a severe acute respiratory syndrome- associated coronavirus-neutralizing human monoclonal antibody reduces disease severity and viral burden in golden syrian hamsters</ET><AU>ROBERTS (Anjeanette); THOMAS (William D.); GUARNER (Jeannette); LAMIRANDE (Elaine W.); BABCOCK (Gregory J.); GREENOUGH (Thomas C.); VOGEL (Leatrice); HAYES (Norman); SULLIVAN (John L.); ZAKI (Sherif); SUBBARAO (Kanta); AMBROSINO (Donna M.)</AU><AF>Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health/Bethesda, Maryland/Etats-Unis (1 aut., 4 aut., 7 aut., 11 aut.); Massachusetts Biologic Laboratories, University of Massachusetts Medical School, Jamaica Plain/Etats-Unis (2 aut., 5 aut., 12 aut.); Infectious Disease Pathology Activity, National Center for Infectious Diseases, Centers for Disease Control and Prevention/Atlanta, Georgia/Etats-Unis (3 aut., 8 aut., 10 aut.); Departments of Pediatrics and Molecular Medicine, University of Massachusetts Medical School/Worcester/Etats-Unis (6 aut., 9 aut.)</AF><DT>Publication en série; Niveau analytique</DT><SO>The Journal of infectious diseases; ISSN 0022-1899; Coden JIDIAQ; Etats-Unis; Da. 2006; Vol. 193; No. 5; Pp. 685-692; Bibl. 30 ref.</SO><LA>Anglais</LA><EA>Background. Immunotherapy with monoclonal antibodies (MAbs) offers safe interventions for the prevention of infection in patients after organ transplantation and for the treatment of cancers and autoimmune diseases. MAb 201 is a severe acute respiratory syndrome-associated coronavirus (SARS-CoV)-specific MAb that prevents establishment of viral replication in vitro and prevents viral replication in vivo when administered prophylactically. The efficacy of MAb 201 in the treatment of SARS was evaluated in golden Syrian hamsters, an animal model that supports SARS-CoV replication to high levels and displays severe pathological changes associated with infection, including pneumonitis and pulmonary consolidation. Methods. Golden Syrian hamsters that were intranasally inoculated with SARS-CoV were treated with various doses of MAb 201 or an irrelevant MAb 24 h after inoculation. Two to 7 days after infection, the hamsters were killed, and their lungs were collected for evaluation of viral titers and pathological findings. Results. Postexposure treatment with MAb 201 can alleviate the viral burden and associated pathological findings in a golden Syrian hamster model of SARS-CoV infection. After a hamster is treated with MAb 201, its viral burden is reduced by 10<sup>2.4</sup>-10<sup>3.9</sup> 50% tissue-culture infectious doses per gram of tissue, and the severity of associated pathological findings, including interstitial pneumonitis and consolidation, is also remarkably reduced. Conclusions. The demonstration of successful postexposure MAb 201 therapy in an animal model that demonstrates viral replication and associated pulmonary pathological findings suggests that MAb 201 may be useful in the arsenal of tools to combat SARS.</EA><CC>002A05C10; 002B05; 002A05F04</CC><FD>Coronavirus; Homme; Hamster; Traitement; Anticorps neutralisant; Anticorps monoclonal; Microbiologie; Infection; Syndrome respiratoire aigu sévère</FD><FG>Coronaviridae; Nidovirales; Virus; Rodentia; Mammalia; Vertebrata; Appareil respiratoire pathologie; Virose; Poumon pathologie</FG><ED>Coronavirus; Human; Hamster; Treatment; Neutralizing antibody; Monoclonal antibody; Microbiology; Infection; Severe acute respiratory syndrome</ED><EG>Coronaviridae; Nidovirales; Virus; Rodentia; Mammalia; Vertebrata; Respiratory disease; Viral disease; Lung disease</EG><SD>Coronavirus; Hombre; Hamster; Tratamiento; anticuerpo neutralizante; Anticuerpo monoclonal; Microbiología; Infección; Síndrome respiratorio agudo severo</SD><LO>INIST-2052.354000153365310100</LO><ID>06-0186247</ID></server></inist></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/PascalFrancis/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000526 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 000526 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SrasV1
|flux= PascalFrancis
|étape= Corpus
|type= RBID
|clé= Pascal:06-0186247
|texte= Therapy with a severe acute respiratory syndrome- associated coronavirus-neutralizing human monoclonal antibody reduces disease severity and viral burden in golden syrian hamsters
}}
| This area was generated with Dilib version V0.6.33. |  |